- Home
- EBC vs BLLN Comparison
EBC vs BLLN Comparison
Compare EBC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBC | BLLN |
|---|---|---|
| Founded | 1818 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EBC | BLLN |
|---|---|---|
| Price | $19.42 | $87.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $21.88 | ★ $137.83 |
| AVG Volume (30 Days) | ★ 1.8M | 259.9K |
| Earning Date | 01-22-2026 | 12-09-2025 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $627,584,000.00 | $254,136,000.00 |
| Revenue This Year | $28.16 | $98.01 |
| Revenue Next Year | $32.65 | $35.84 |
| P/E Ratio | $79.56 | ★ N/A |
| Revenue Growth | 3.01 | ★ 254.30 |
| 52 Week Low | $13.51 | $80.51 |
| 52 Week High | $20.19 | $138.70 |
Technical Indicators
Market Signals| Indicator | EBC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | N/A |
| Support Level | $18.81 | N/A |
| Resistance Level | $19.47 | N/A |
| Average True Range (ATR) | 0.41 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 69.81 | 0.00 |
Price Performance
Historical ComparisonAbout EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.
About BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.